Drug intelligence / Profile preview

Fostrap

Development stage: Discontinued
Lead developer: Università degli Studi di Messina
Administration: Intraperitoneal

Overview

Fostrap is a discontinued drug candidate that was originally developed by the University of Messina for potential therapeutic applications in the fields of endocrinology and metabolic diseases. Publicly available information regarding the compound is extremely limited; its specific active ingredient, molecular target, and chemical modality (such as whether it is a small molecule or a biologic) have not been disclosed. The project's research and development status is currently classified as discontinued globally, and there is no evidence of recent clinical or preclinical activity.

Beyond the preview

Go deeper on Fostrap.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fostrap.

Explore the full profile